Cagrilintide

Overview

Cagrilintide (AM833) is a long-acting, acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead path is the CagriSema co-formulation with semaglutide, and standalone cagrilintide was deprioritized after Phase 2 in favor of the combination.

Mechanism of Action

Cagrilintide is an amylin receptor agonist acting at AMY1/AMY3 complexes (calcitonin receptor plus RAMP1/RAMP3) in the area postrema and nucleus tractus solitarius, with additional calcitonin-receptor activity. It promotes postprandial satiety and slows gastric emptying. A C18 fatty-diacid side chain enables reversible albumin binding and an extended half-life of roughly six days. Paired with semaglutide, the amylin and GLP-1 mechanisms suppress appetite through distinct hypothalamic and brainstem pathways.

Research Summary

A Phase 2 dose-finding trial of cagrilintide monotherapy demonstrated dose-dependent weight loss of up to 10.8% over 26 weeks versus 3.0% for placebo (Lau et al., The Lancet, 2021). Novo Nordisk pivoted development to the CagriSema co-formulation with semaglutide 2.4 mg. The Phase 3 REDEFINE 1 trial (n=3,417, 68 weeks) in obesity reported ~22.7% mean body weight reduction on the treatment-policy estimand, with 91.9% achieving ≥5% weight loss versus 31.5% for placebo. Novo Nordisk submitted a CagriSema NDA to the FDA in December 2025; the application is under review in 2026. Cagrilintide is not FDA-approved as a standalone therapy, and CagriSema is not yet approved as of April 2026.

Vendors selling Cagrilintide

Scored vendors carrying Cagrilintide, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Prescribers who offer Cagrilintide

3 prescribers in our directory work with Cagrilintide, each confirmed from their own website. Peptides like Cagrilintide require a prescription from a licensed provider — telehealth options are available.

Reported Side Effects

• Nausea (dose-dependent, most common adverse event)
• Injection site reactions (erythema, pain, pruritus)
• Diarrhea
• Vomiting
• Constipation

Biomarkers researchers track for Cagrilintide

These biomarkers appear in the research literature as measures of response and safety for this compound.

Related Peptides

Compare Cagrilintide with Others

Research References

• Lau DCW, et al. Once-weekly cagrilintide for weight management in adults with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172.
• Novo Nordisk. REDEFINE 1 Phase 3 trial of CagriSema (cagrilintide + semaglutide); FDA NDA submitted December 2025.

Frequently asked questions

Has Cagrilintide been independently lab-tested?

Disclosed Labs has collected 87 Certificates of Analysis (COA) for Cagrilintide from 13 independent testing labs. 26 vendors have submitted material for testing. Products average 99.7% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/cagrilintide/testing.

What is the average purity of Cagrilintide on the market?

Based on 87 COAs analyzed by Disclosed Labs, Cagrilintide products average 99.7% (±0.2%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/cagrilintide/coas.

Which labs have tested Cagrilintide?

Independent labs that have tested Cagrilintide include: ILS Labs (Grade A). Full lab credibility grades and profiles are at https://www.disclosedlabs.com/labs.

Where can researchers source Cagrilintide?

8 vendors with Disclosed Labs trust grades currently list Cagrilintide, including Glacier Aminos, Ion Peptide, Peptide Partners. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/cagrilintide.

Which prescribers offer Cagrilintide with a prescription?

3 prescribers in the Disclosed Labs directory work with Cagrilintide, each confirmed from their own website, with telehealth options available. Cagrilintide requires a prescription from a licensed provider. Browse them at https://www.disclosedlabs.com/prescribers?peptide=Cagrilintide.

How does Cagrilintide work?

Cagrilintide is an amylin receptor agonist acting at AMY1/AMY3 complexes (calcitonin receptor plus RAMP1/RAMP3) in the area postrema and nucleus tractus solitarius, with additional calcitonin-receptor activity. It promotes postprandial satiety and slows gastric emptying. A C18 fatty-diacid side chain enables reversible albumin binding and an extended half-life of roughly six days. Paired with semaglutide, the amylin and GLP-1 mechanisms suppress appetite through distinct hypothalamic and brainstem pathways.

What does the research say about Cagrilintide?

A Phase 2 dose-finding trial of cagrilintide monotherapy demonstrated dose-dependent weight loss of up to 10.8% over 26 weeks versus 3.0% for placebo (Lau et al., The Lancet, 2021). Novo Nordisk pivoted development to the CagriSema co-formulation with semaglutide 2.4 mg. The Phase 3 REDEFINE 1 trial (n=3,417, 68 weeks) in obesity reported ~22.7% mean body weight reduction on the treatment-policy estimand, with 91.9% achieving ≥5% weight loss versus 31.5% for placebo. Novo Nordisk submitted a CagriSema NDA to the FDA in December 2025; the application is under review in 2026. Cagrilintide is not FDA-approved as a standalone therapy, and CagriSema is not yet approved as of April 2026.